Digital Therapeutics Specialist Hi, Invited to 'BioUSA' Company Introduction Session

Introduction to pipeline and R&D activities over 13 minutes
Announcement of 'Alzguard', a screening tool for mild cognitive impairment expected

Kim Jin-woo, CEO of Hi, presenting at the Spring Academic Conference of the Korean Dementia Association.

[Asia Economy Reporter Lee Gwanju] HAII, a digital therapeutics specialist company, announced on the 20th that it has been invited to the 'Company Presentation' session at the '2022 BIO International Convention (BIO USA)' to be held in the United States next month.

Celebrating its 29th edition this year, BIO USA is the world's largest pharmaceutical and biotechnology expo. This year, it will be held in San Diego, USA, from June 13 to 16. HAII has secured a 13-minute presentation opportunity in the BIO USA Company Presentation session. The Company Presentation is one of the most attention-grabbing programs during the BIO USA event, where companies introduce their pipelines, research and development (R&D) activities, business, and investment goals.

In this presentation, HAII plans to introduce the diagnostic accuracy of its mild cognitive impairment screening digital biomarker, 'Alzguard,' along with its major pipeline. The presentation is scheduled for 2 PM (local time) on June 13. HAII will also hold meetings regarding clinical progress and joint projects of therapeutics under development with leading global companies and research institutions to globalize digital therapeutics.

Jinwoo Kim, CEO of HAII, said, “We are honored to be invited to BIO USA and to have the opportunity to present our company,” adding, “At a time when digital therapeutics are gaining attention from the global biotech industry, we will effectively communicate that Korean digital therapeutics technology has reached a significant level.”

This content was produced with the assistance of AI translation services.